TrialHaematologica2026

Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.

Pau Abrisqueta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.